Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is making strides in neurological health with a two-pronged strategy that includes an investigational therapy for multiple sclerosis (MS) and a dietary supplement aimed at alcohol metabolism. The company is developing Lucid-MS, a patented new chemical entity designed to target the enzyme PAD2, which is associated with myelin degradation. Unlike traditional MS treatments that primarily modulate the immune system, Lucid-MS aims to protect and potentially restore the myelin sheath, the protective covering of nerve fibers that is damaged in MS. This approach could represent a significant shift in how MS is treated, potentially offering a disease-modifying therapy that addresses the underlying pathology rather than just managing symptoms.
Quantum BioPharma has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 trial of Lucid-MS. The company is also collaborating with Massachusetts General Hospital on imaging studies to support the development of the therapy. This collaboration is crucial for monitoring the effects of Lucid-MS on myelin integrity in clinical trials, providing objective biomarkers to assess efficacy.
In parallel, Quantum BioPharma is advancing unbuzzd, a proprietary dietary supplement designed to support alcohol metabolism and reduce acute intoxication and hangover effects. The company cites results from a randomized, placebo-controlled clinical trial demonstrating its effectiveness. unbuzzd is being marketed by Unbuzzd Wellness Inc. (UWI), a company led by industry veterans, with Quantum BioPharma retaining a 19.84% ownership stake as of March 31, 2026. The agreement includes royalty payments of 7% of sales until cumulative payments reach $250 million, after which the royalty rate drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
The dual strategy positions Quantum BioPharma to address two significant unmet medical needs: MS and alcohol misuse. MS affects approximately 2.8 million people worldwide, and current treatments often have limited efficacy or significant side effects. An approach that targets myelin repair could be a game-changer. Meanwhile, alcohol misuse is a major public health issue, and a supplement that can mitigate its acute effects could have broad appeal.
The advancement of Lucid-MS into Phase 2 trials is a critical milestone, as it moves the therapy closer to potential approval. The collaboration with Massachusetts General Hospital adds credibility and expertise, enhancing the likelihood of successful trial outcomes. For unbuzzd, the commercial partnership with UWI and the royalty structure provide a revenue stream while allowing Quantum BioPharma to retain rights for pharmaceutical applications.
Investors and stakeholders are watching these developments closely, as both programs have the potential to create substantial value. The company's focus on innovative solutions for challenging neurological conditions aligns with a growing demand for more effective treatments. As Quantum BioPharma continues to advance its pipeline, the outcomes of the Phase 2 trial and the commercial success of unbuzzd will be key indicators of its future trajectory.
For more information, visit the company's newsroom at https://ibn.fm/QNTM.
